Ono Pharmaceutical will present positive results from the Phase 2 PROSPECT study of tirabrutinib for relapsed or refractory primary central nervous system lymphoma at ASCO 2025 in Chicago.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.